By R. Kippler. Florida Christian College.
Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear Setting C om m ents G an 2005 M ulticenter Janicki Alsohasinform ationongenotyping inform ationforCYP2D 6 2006 HersheyM edical Center K h an N E E D TablesandF igures 2005 G eneralhospital N aguib N oprem edicationwasgivenandptsfastedfrom m idnightbeforesurgery 5 mg lipitor with mastercard cholesterol test variance. Aftertrachealintubation buy generic lipitor 20mg on-line cholesterol levels postpartum,allptshadanorogastric tubeplacedto 1996 ensurebaselineem ptying of thestom ach of airandgastric contents. Allorogastric tubeswererem ovedattheendof surgeryandbeforetracheal N R ex tubation. R etching wasnotassessedseparatelyfrom vom iting andnausea. If nauseaorvom iting occurred,rescueantiem etic treatm entof m etoclopram ideiv10m g wasadm inistered. F orpost-operativeanalgesia,m eperidineim 50m g wasadm inisteredif painscorewas ≥ 5. Study alsoincludedam etoclopram idearm (n= 24)andaplaceboarm (n= 29),buttheseresultsarenotincludedinthisdataabstraction. Afterintubation theconcentrationsof thenitrousox ide,ox ygen,carbondiox ide,andisofluraneweredeterm inedcontinuouslybyam ultiple-gasanaesthesia m onitor. Abdom inalinsufflationforthelaparoscopic procedurewasaccom plishedwith carbondiox ide. Antiemetics Page 339 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 9. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear A llow oth er R un-in/ Setting Design Exclusioncriteria Intervention m edication W ash out O ksuz R CT,D B, Thosewith cardiovascular,pulm onary,renal,hepatic or M etoclopram ide10m g R escuem edicationwas N R /N o 2007 Parallel neurologic diseaseswereex cluded. Aswellasthose G ranisetron40m cg/kg perm itted antiem etic within N R receiving drugsknow tohaveantiem etic effects,such as O ndansetron15m cg/kg iv 48hoursof tricyclic antidepressants,scopolam ine,phenothiaz ines, surgery laraz epam ,corticosteroids,andtrim ethobenz am ides;had ex periencednauseaorvom iting,orwhohadreceived antiem etic treatm entinthe48hoursbeforesurgery. W h ite R CT,ACT,Ptswith historyof allergytoanyof thepotentialstudy G ranisteron(1m g) D ex am ethasone4m g N R /N o 2006 D B m edications,pregnancy,breastfeeding,active O ndansetronIV (4m g) IV giventoallafter antiem etic or M ulticenter m enstruation,vom iting orretching within24h beforethe induction psychoactive U SA operation,adm inistrationof antiem etic orpsychoactive m edication m edicationwithin24h beforesurgery,ahistoryof severe Cisatracurium 0. M etocloparm ide10m g IV wasusedasrescue therapy O ndansetron: O DT vs IV Antiemetics Page 340 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 9. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or A ge/ Screened/ W ith drawn/ Y ear G ender/ Eligible/ L ostto fu/ Setting Eth nicity Enrolled A nalyz ed O th erpopulationch aracteristics O ksuz 39. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear Setting R esults A dverse Events O ksuz Incidenceof PO N V (0-3h aftersurgery) N R 2007 M et:12% vsG ran:0% vsO nd:12% N R Incidenceof PO N V (4-24h aftersurgery) M et:44% vsG ran:4% vsO nd:12% (p<0. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear Setting C om m ents O ksuz 2007 N R W h ite Subanalysisof outpatientvsinpatient. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear A llow oth er R un-in/ Setting Design Exclusioncriteria Intervention m edication W ash out Dem iraran R CT,D B Thosewhohadex periencednauseaorvom iting 24hours O D T ondansetron8m g and5 M etoclopram ide10m g N R /N R 2005 beforethestudyorwhoweretaking antiem etic m edication m L norm alsalineIV IV wasusedasrescue SingleSite m edication Turkey IV ondansetron4m g in5m L salineandoralplacebo Placebo:5m lnorm alsalineIV andoralplacebo Pirat R CT,D B Ptswith historyof m otionsicknessorPO N V,preoperative O D T ondansetron8m g and5 IM injectionof N R /N o 2005 pruritus,treatm entwith opioidsorantiem eticswithin48 m L norm alsalineIV diclofenac sodium antiem etic within N R hoursof surgery,hypersensitivitytoondansetron, 100m g wasusedfor 48hoursof m orphine,orbupivacaine,andcontraindicationforor IV ondansetron4m g in5m L postoperativepain surgery refusalorspinalanesthesia. Casesinwhich dural salineandoralplacebo puncturecouldnotbeperform edoropioidswererequired R escuem edicationwas tocontrolintraoperativeorpostoperativepainwerealso Placebo:5m lnorm alsalineIV perm itted ex cluded. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or A ge/ Screened/ W ith drawn/ Y ear G ender/ Eligible/ L ostto fu/ Setting Eth nicity Enrolled A nalyz ed O th erpopulationch aracteristics Dem iraran 47. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear Setting R esults A dverse Events Dem iraran O D T vsIV vsPla O D T vsIV vsPla 2005 Incidenceof nauseaorvom iting (1stm in) Headache:13% vs17% vs15% SingleSite N ausea:28% vs25% vs55% (p<0. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear Setting C om m ents Dem iraran D atapresentedingraphs,num bersareestim atesof thegraphs. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear A llow oth er R un-in/ Setting Design Exclusioncriteria Intervention m edication W ash out Diem unsch R CT,D B E x clusioncriteriaincludedpregnancy/breastfeeding Aprepitant40m g,orally Prem edication,as N o/no 2007 status,needforanasogastric ororal-gastric tube,useof Aprepitant125m g,orally needed prophylactic M ulticenter neuroax ial-orpropofol-m aintainedanaesthesia,vom iting O ndansetron4m g iv antiem etics within24h beforesurgeryorof anyorganic aetiology, rescuem edication within24h allergytoanym edicationstobeusedbeforeoperationor (chosenby beforesurgery intra-operatively,pre-establishedneedforintensivecare investigator) orstep-downunitcareafteroperation,evidenceof diseaseorhistoryof illnesswhich according tothe investigatorrenderedthepatientinappropriateforthe study,abnorm alpreoperativelaboratoryvalues(aspartate am inotransferase>2. M edicationsknowntoinduceCYP3A4were prohibitedwithin30daysof thestudystartandCYP3A4 inhibitorswereprohibited7daysbeforestartof study. G an R CT,D B Patientswhowerepregnantorbreast-feeding,undergoing Aprepitant40m g orally R escuem edicationwas N o/no 2007 surgeryrequiring routineplacem entof anasogastric or Aprepitant125m g orally perm itted prophylactic M ulticenter oral-gastric tube,orreceiving spinalregionalorpropofol- O ndansetron4m g iv antiem etics m aintainedanesthesia. Ptswhom werevom iting of any within24hours organic etiology,hadvom itedforanyreasonwithin24 beforesurgery hoursof surgery,orhadabnorm allaboratoryvaluesas specifiedbytheprotocol(alanineam inotransferaseof aspartateam inotransferase>2. Thosetaking m edicationsm etaboliz edbyCYP3A4wereex cluded. Dolasetronvs G ranisetronvs O ndansetron Antiemetics Page 348 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 9. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or A ge/ Screened/ W ith drawn/ Y ear G ender/ Eligible/ L ostto fu/ Setting Eth nicity Enrolled A nalyz ed O th erpopulationch aracteristics Diem unsch 45. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear Setting R esults A dverse Events Diem unsch Aprepitant40m g vsAprepitant125m g vsO ndansetron4m g M ostcom m onAE sreported: 2007 Com pleteR esponse Pyrex ia:8. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear Setting C om m ents Diem unsch 2007 M ulticenter G an 2007 M ulticenter Dolasetronvs G ranisetronvs O ndansetron Antiemetics Page 351 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 9. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear A llow oth er R un-in/ Setting Design Exclusioncriteria Intervention m edication W ash out B ridges D B,R CT Allergyto5-HT3R A drugsorpreviousintolerance, D olasetron12.
The small numbers of patients in these trials often limited the ability to show a difference between drugs if one exists generic lipitor 5 mg free shipping daily cholesterol intake chart. Depending on the definition used buy 20 mg lipitor fast delivery cholesterol chart mmol, there was lack of clarity on the relationship of response Attention deficit hyperactivity disorder 24 of 200 Final Update 4 Report Drug Effectiveness Review Project rate to clinical significance. Response rates of nonstimulants varied, but the range in placebo-controlled trials was similar to that found with stimulants. Significant variation in the method of assessment and definition of response was most likely the reason for the wide variation. Effectiveness • Because no trials of effectiveness were found, observational studies were assessed for outcomes of effectiveness. Methodologic concerns over this study suggested caution in interpretation of these findings. Emancipated living situation and level of relationship commitment was associated with response to methylphenidate. Early response to methylphenidate was negatively associated with high school graduation, however. Methodological limitations of these studies severely limited the interpretation of these findings. Again, significant methodologic limitations suggested caution in interpreting results. Efficacy and tolerability Young children (preschool age; 3-5 years) • Comparative evidence in young children was not found. Children (elementary school age; 6-12 years) Stimulants • Immediate-release compared with extended-release formulations Attention deficit hyperactivity disorder 25 of 200 Final Update 4 Report Drug Effectiveness Review Project o The evidence regarding immediate-release methylphenidate compared with methylphenidate OROS was conflicting, with 2 double-blind trials unable to identify differences, while 2 open-label studies found that methylphenidate OROS resulted in greater improvements on some but not all assessments. Overall, the studies were unable to identify differences between methylphenidate SR and immediate-release methylphenidate, and methylphenidate CD was found to be noninferior to immediate-release methylphenidate. Methodologic concerns indicate caution in interpreting this evidence. However, these results should be interpreted with caution until higher quality evidence is available. Methodologic concerns indicate caution in interpreting these findings. A difference was found up to 6 hours post dose, but methylphenidate OROS resulted in better scores later in the day; from 10 to 12 hours post dose. Evidence from short-term trials and observational studies suggested that weight loss is greater with immediate-release dextroamphetamine than immediate-release methylphenidate. Very limited evidence suggested that twice daily dosing of immediate-release mixed amphetamine salts led to higher rates of Attention deficit hyperactivity disorder 26 of 200 Final Update 4 Report Drug Effectiveness Review Project loss of appetite and sleep trouble than once daily dosing of immediate-release methylphenidate. Transient weight loss was greater with mixed amphetamine salts and dextroamphetamine SR than with immediate-release dextroamphetamine. However, this evidence should be interpreted with caution. Rates of specific adverse events were not available for the individual treatment groups, but the data dossier did not specify any differences between them. Methylphenidate transdermal system was found to have similar efficacy to immediate-release methylphenidate over 12 hours in a simulated classroom setting, starting 30 minutes after dosing. Differences in adverse events were not found between methylphenidate transdermal system and immediate-release methylphenidate. Nonstimulants Atomoxetine • Atomoxetine compared with methylphenidate o Evidence from 2 trials suggested that atomoxetine is associated with efficacy outcomes similar to immediate-release methylphenidate. However, in the smaller subgroup without prior stimulant exposure, the 2 drugs were not found to be statistically significantly different in response rates. Immediate-release clonidine • Current evidence does not clearly identify a difference in improvement of ADHD symptoms between immediate-release clonidine and immediate-release methylphenidate in children with ADHD (both with comorbid Tourette’s disorder and without). Inconsistency in some outcomes suggests caution in interpreting these results. Extended-release clonidine • No evidence directly comparing extended-release clonidine to another ADHD medication was found. Flexible dosing resulted in similar Attention deficit hyperactivity disorder 28 of 200 Final Update 4 Report Drug Effectiveness Review Project rates between placebo and clonidine groups. Somnolence and fatigue were more common in the clonidine groups than placebo, and peaked at 2 weeks.
Philadelphia: Wolters Kluwer order lipitor 10mg online cholesterol test san antonio, Lippincott purchase lipitor 40 mg with mastercard cholesterol kit, Wiliams & Wilkins, 2011;476–85 TREATMENT OF ABNORMAL UTERINE 4. BJOG 2004;111:734–40 Treatment of AUB is described in chapters about 5. Oral the causes of AUB: fibroids and cervical cancer, progestogens vs levonorgestrel-releasing intrauterine and in Chapter 20 about the treatment of func- system for endometrial hyperplasia: a systematic review tional AUB. Report of an informal FLOWCHART: PREMENOPAUSAL working group on urogenital schistosomiasis and ABNORMAL BLEEDING HIV transmission. Geneva: WHO, 2009 In the flowchart history taking (duration of the 7. Evaluation of problem) and examination (speculum examination endometrial thickness with transvaginal ultrasonography and vaginal examination) are used to stratify to and histopathology in premenopausal women with appropriate treatment (Figure 2). Arch Gynecol Obstet 2009; some women with a short duration of complaints 282:395–9 8. Saline contrast hysterosonography in abnormal uterine bleeding: a systematic review and meta-analysis. Clinical practice guidelines on menorrhagia: manage- ment of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol 2010;152:133–7 95 . It is more fre- quent in women with obesity or a long history Vaginal bleeding in the postmenopausal period is of polycystic ovary syndrome (see Chapter 16 always abnormal and needs detailed history taking, on subfertility) and anovulatory cycles. Hyper- speculum examination and bimanual vaginal exam- plasia with atypical cytological features is more ination. Many women need additional tests like likely to progress into uterine cancer (25–40%) visual inspection with acetic acid (VIA) and ultra- than hyperplasia without atypical cytological sound to rule out cervical (pre)malignancy and features that becomes malignant in only a few endometrial cancer or bleeding from other sources patients. Definition Sometimes the polyp is ‘born’ and visible on A woman is postmenopausal if her periods have speculum examination. CAUSES OF POSTMENOPAUSAL VAGINAL • Endometrial cancer: blood loss is often the first BLEEDING sign. It is very uncommon in women below • Atrophy: the cells of the urogenital system have the age of 40 years, but in all postmenopausal estrogen receptors. After the menopause the women with bleeding problems it should be urogenital system becomes atrophic and the considered. Other symptoms uterus is more common in black women. Blood are dyspareunia (pain during intercourse), urine loss, pain and abdominal mass are the most fre- incontinence or urinary frequency (frequent quent symptoms. Sarcoma can present pre- or need to urinate) or vaginal discharge. This can cause vaginal bleed- • Urogenital schistosomiasis: this can cause abnormal ing due to infection. Treatment is simple: re- bleeding in postmenopausal women and can move the IUD. A cervical biopsy can be • Contraception before menopause (IUD)? For EXAMINATION endometrial sampling (do this in postmeno- pausal women with thickened endometrium • Obesity: women with morbid obesity [body >3–4mm on ultrasound) you could use the mass index (BMI) >30; see Chapter 8 on how to smallest cannula of a manual vacuum aspiration calculate BMI] have a high level of estrogen. The big advantage of N Signs of atrophy: pale, dry vagina sometimes a MVA is that you can perform this without with petechia (small red spots caused by sub- anesthesia in most women. D&C is that if postmenopausal blood loss is N Prolapse with pressure sores? Make sure you can send the sample N Vaginal discharge? N If possible perform a test for pre-stadia of • Hysteroscopy is an advanced diagnostic test: cervical cancer like a human papillomavirus with a scope you can inspect the inside of the (HPV) test or a VIA; see Chapter 26. In many low-resource settings this is not N Presence of grainy sandy patches – alterations available yet (see Chapter 1). If you suspect TREATMENT advanced cervical carcinoma do a rectal exami- Endometrial malignancies need a hysterectomy nation as described in Chapter 1. Second-best therapy is oral progestogens like medroxyprogesterone acetate (10mg/day for 3 months).
For venlafaxine-treated 295 patients 10 mg lipitor overnight delivery cholesterol medication recommendations, neither age (< 50 or > 50 years of age) nor sex affected remission rates discount lipitor 20 mg without prescription cholesterol lowering foods and herbs. Among patients treated with SSRIs, however, a significant interaction was observed between treatment and sex (P=0. Remission rates for older women treated with venlafaxine (48%) were higher than remission rates for older women treated with SSRIs (28%, P=0. Hormone replacement therapy appeared to eliminate these differences. Additional analyses of age subgroups (< 40, 41- 54, 55-64, and > 65 years of age) and sex subgroups revealed that no significant age-by- treatment, sex-by-treatment, or age-by-sex-by-treatment interactions occurred. Men and women of different ages within each treatment group had similar rates of remission, response, and 294 absence of depressed mood. Among patients over 40 years of age, the rates of adverse events were similar between the treatment groups, although venlafaxine-treated patients aged 55 to 64 years reported significantly more nausea than placebo (P<0. Bupropion compared with paroxetine One fair RCT examined the efficacy of bupropion SR (100-300 mg/d) and paroxetine (10-40 111, 112 mg/d) in 100 outpatients ages 60 years or older (range 60-88 years) over 6 weeks. The majority of patients were white (bupropion SR, 98%; paroxetine, 90%), female (bupropion SR, Second-generation antidepressants 92 of 190 Final Update 5 Report Drug Effectiveness Review Project 54%; paroxetine, 60%), and did not use antidepressants for the current episode before enrollment (bupropion SR, 83%; paroxetine, 88%). The overall loss to follow-up was 16 percent with no significant difference between treatment groups. Efficacy according to any outcome measure did not differ significantly between treatment groups. Response rates (≥ 50% reduction in HAM-D scores) were similar in both groups (bupropion SR, 71%; paroxetine, 77%). Quality-of-life scales (QLDS, SF-36) showed statistically significant improvements in both treatment groups from baseline to endpoint (P<0. Ethnicity No studies directly compared the efficacy, effectiveness and harms of second-generation antidepressants among different races or ethnicities. Therefore, we summarize results of studies that compared second-generation antidepressants with placebo. Duloxetine compared with placebo Two pooled analyses of seven placebo-controlled duloxetine trials assessed the efficacy and 296 297 tolerability of duloxetine in Hispanic and African American patients compared to Caucasian patients. The first analysis included 1,342 Caucasians and 120 Hispanics and found no difference 296 in efficacy outcomes for Hispanics and Caucasians. There were no significant differences between groups in discontinuation rates due to adverse events ir in the types or occurrence of specific adverse events. The second analysis of 1,300 Caucasians and 123 African Americans also found no evidence for a differential effect of duloxetine in African-American and Caucasian 297 patients in efficacy or safety outcomes. Fluoxetine compared with placebo An RCT examined ethnic differences in response to antidepressant treatment among depressed 298 HIV-positive patients. A total of 118 patients were randomized to either fluoxetine (20-80 mg/d) or placebo for 8 weeks. Of all participants, 67 percent were White, 19 percent Black, and 14 percent Latino; only 1. Loss to follow-up was significantly greater among Latinos (53%) than among Blacks (14%) and Whites (28%; P<0. Ethnicity was not associated with the total number of treatment emergent side effects or dosage. Among completers within the active-treatment group, Whites were more likely to respond to treatment than the other two groups (84% compared with 50% in Blacks and 67% in Latinos). Among completers in the placebo group, Latinos were more likely to show treatment response (80%) than were blacks (36%) or whites (43%). However, a statistical analysis of these findings was not possible because of the low number of Latinos who completed the study. Paroxetine compared with placebo A pooled analysis of 104 paroxetine trials (14,875 patients) detected slightly lower response rates 299 for Hispanics and Asians than for Blacks and Whites. Citalopram One study that did not meet our inclusion criteria performed a secondary analysis of data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study to compare 300 remission and response rates among Blacks, Whites, and Hispanics with nonpsychotic MDD. Second-generation antidepressants 93 of 190 Final Update 5 Report Drug Effectiveness Review Project We briefly describe it here because because of the paucity of evidence on this topic. STAR*D included outpatients in 23 psychiatric and 18 primary care centers.
Gauthier S 20 mg lipitor visa keeping cholesterol levels down, Feldman H lipitor 5mg without a prescription cholesterol on keto, Hecker J, Vellas B, Ames D, Subbiah P, et al. Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P. Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, et al. Potkin SG, Anand R, Hartman R, Veach J, Grossberg G. Rive B, Vercelletto M, Damier FD, Cochran J, Francois C. Minimal clinically important difference, sample size and trial duration. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. International Journal of Geriatric Psychopharmacology 1998;1(Suppl 1):S20-S25. Adverse effects associated with the use of donepezil in general practice in England. Farlow M, Brashear A, Hui S, Schneider L, Unverzagt F, and TSG. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Feldman H, GauthierS, Hecker J, Vellas B, Subbiah P, Whalen E, et al. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Y ear:1998 PO PU L A T IO N G roupssimilar atbaseline:N R C H A R A C T ER IST IC S: A lzh eimer classification:M ild-m oderate rivastigmine4 mg/d rivastigmine6 mg/d placebo M eanage(years): 68. Y ear:1998 A DV ER SEEV EN T S: rivastigmine4 mg/d rivastigmine6 mg/d placebo O veralladverseeffectsreported: N R N R N R • N ausea 17% 31% 6% • V om iting 10% 18% 3% • D iarrhea 7% 12% 2% • D izziness 6% 20% 7% • H eadache 4% 13% 6% Significantdifferencesinadverse Significantlym orepatientssufferedfrom nausea,vom iting,diarrhea,dizziness,andheadacheinR IV events: groupsespeciallyathigherdoses;P = N R A N A L Y SIS: IT T :N o Postrandomizationexclusions:N R A DEQ U A T ER A N DO M IZ A T IO N : N R A DEQ U A T EA L L O C A T IO N Y es C O N C EA L M EN T : B L IN DIN G O F O U T C O M E Y es A SSESSO R S: A T T R IT IO N (overall): O veralllossto follow-up: 11. Y ear:2004 C H A R A C T ER IST IC S O F D O N givenatanydoseform orethanonedaywithparallelconcom itantplacebogroup;outcom em easures IN T ER V EN T IO N S: included:G lobalassessm ent(CIBIC-plus,G BS,M E N F IS,CD R -SB,A D A S-Cog,M M SE );A D L ’s(PD S, D A D ,IA D L ,PSM S,CM CS);behavioraldisturbances;Q O L ;caregiverstress;sideeffects M A IN R ESU L T S: Q ualityoflife • N osignificantdifferencebetweenD O N andplaceboforQ O L andbehavioraldisturbance A ctivitiesofdailyliving • Pooleddatafrom 2studiesprovidedevidenceof benefitof D O N at12and24weeks(P <0. Y ear:2004 A DV ER SEEV EN T S: W ith drawalsdueto adverseevents: A m eta-analysisof withdrawalsbeforetheendof treatm entshowed nosignificantdifferencesbetweenthe5m g/dgroup andtheplacebogroup at12and24weeks;therewere significantdifferencesforthe10m g/dgroup infavorof placeboat12,butnotat24and52weeks(29/184 D O N ,13/178placebo)(O R 2. Y ear:2004 C ountry:M ultinational F U N DIN G : N H S R &D E x ecutiveU K DESIG N : Studydesign:M eta-analysis N umber ofpatients:8trialsinvolving 3,450participants A IM S O F R EV IEW : Todeterm inetheclinicalefficacyandsafetyof R IV forpatientswithdem entiaof A lzheim er’stype ST U DIES IN C L U DEDIN A totalof 8studies:A gidetal. Y ear:2004 C H A R A C T ER IST IC S O F R IV givenatanydosewithparallelplacebocontrol;outcom em easuresincluded:dependency,global IN T ER V EN T IO N S: im pression,functionalperform ance,cognitivefunction,behavioraldisturbance,Q O L ,effectoncaregiver, death,institutionalizationrates,withdrawals,incidenceof adverseevents M A IN R ESU L T S: • M eta-analysisof A D A S-Cog W M D srevealsstatisticallysignificantbenefitof R IV 6/12m g/d over placeboat26weeks(W M D -2. Y ear:2004 A DV ER SEEV EN T S: • W ithdrawalsforanyreasonbeforetheendof treatm entshow thattherearenosignificant differencesbetweenwithdrawalsinthe1-4m g/dR IV group andplacebogroup at12and26weeks; therearesignificantdifferencesforthe6-12m g/dgroup infavorof placeboat12,18and26weeks; (20/133vs. Y ear:2004 C O M PR EH EN SIV E R eferstoCochraneD em entiaandCognitiveIm provem entG roup searchstrategy;trialswereselectedfrom L IT ER A T U R ESEA R C H SpecializedR egisterof theCochraneD em entiaandCognitiveIm provem entG roup,containing recordsfrom ST R A T EG Y anum berof publishedandunpublishedelectronic databases(e. Y ear:2005 PO PU L A T IO N G roupssimilar atbaseline:Y es C H A R A C T ER IST IC S: A lzh eimer classification:M ildtom oderate galantaminePR C galantamine placebo M eanage(years): 76. Y ear: 1999 C ountry:M ultinational(9countries) F U N DIN G : E isaiInc.
According to the measurements of cryptococcal clearance in the CSF generic lipitor 20mg without a prescription cholesterol chart mmol, two small randomized studies in Thailand and Vietnam buy lipitor 5 mg online how much cholesterol in one large shrimp, the combination of amphotericin B and flucyto- sine was the most effective treatment (Brouwer 2004, Day 2013). It was even significantly better than triple therapy and also amphotericin B and fluconazole. Amphotericin B at a dosage of 1 mg/kg plus is possibly more rapidly fungicidal than is standard-dose amphotericin B (Bicanic 2008). If amphotericin B is not available, the combination of flucytosine and fluconazole is better than fluconazole alone (Nussbaum 2010). Nevertheless, in view of the toxicity of flucytosine, available in many countries only in infusion and not in tablet form, the combination of amphotericin B and flu- conazole is preferable. In a Phase II study the high doses of 800 mg fluconazole daily was most effective (Pappas 2009). A newer study showed that the efficacy of high dose fluconazole is equivalent to flucytosine (Loyse 2012). In addition to having significantly lower toxicity, liposomal amphotericin (Ambisome) is slightly more effective than conventional amphotericin B (Leenders 1997, Hamill 1999). However even Ambisome-containing combinations are highly toxic. Daily monitoring of kidney and liver enzymes, blood count and electrolytes are recommended. Fluconazole should be administered as an infusion, particularly if patients seem confused. In untreated patients, ART is typically started during the acute phase of treatment. Caution should be taken with tenofovir, given an observed case of renal failure requir- ing dialysis after treatment with tenofovir and amphotericin B. Since there is also a higher risk for the development of IRIS, the optimal time for initiation of ART is still under debate. In ACTG 5164, early ART was an advantage (Zolopa 2009). In a small African study on seriously ill patients, however, mortality was increased in patients 388 AIDS starting ART immediately after diagnosis (Makadzange 2010). In a study on 177 HIV+ adults in Uganda and South Africa who had cryptococcal meningitis and had not previously received ART, deferring ART for 5 weeks after the diagnosis of meningitis was associated with significantly improved survival, as compared with initiating ART at 1 to 2 weeks, especially among patients with a paucity of white cells in cerebro- spinal fluid (Boulware 2014). In cases of isolated pulmonary involvement (CSF-negative) or other extracerebral manifestations, treatment without flucytosine can be completed (acute therapy with amphotericin B and fluconazole) within two instead of four weeks. If there is a pos- itive cryptococcal antigen test without evidence of CNS, pulmonary or other infec- tion, then treatment can consist of fluconazole alone. Treatment success is monitored based on the clinical course and repeated lumbar punctures. CSF is negative in approximately 60% of cases after two weeks (Saag 2000). When this is the case, maintenance therapy or secondary prophylaxis can be started, though not sooner than after four weeks of acute therapy. The quicker the CSF shows to be negative, the better the prognosis (Bicanic 2009, Chang 2012). If there is increased intracranial pressure, then CSF drainage may become necessary (Graybill 2000). There is some evidence that therapeutic lumbar punctures are beneficial (Rolfes 2014). Treatment/prophylaxis of cryptococcosis (daily doses, unless specified otherwise), see also Drugs section for further details Acute therapy Duration: always at least six weeks Treatment of choice Amphotericin B Amphotericin B 0. In this case the daily doses of fluconazole should be 800 mg. Instead, we begin with ART in the acute therapy phase in these patients who are almost always ART- naïve.